To systematically discuss the dual regulatory roles of MIF in atrial fibrillation (AF) and its potential as a biomarker and therapeutic target.
Approach:
Mechanistic Insights: MIF drives atrial electrical remodeling by promoting pro-inflammatory cytokine release, modulating ion channels, disrupting calcium homeostasis, and downregulating connexin 43.
Structural Remodeling: MIF promotes atrial structural remodeling and fibrosis through fibroblast activation, collagen deposition enhancement, and modulation of the TGF-β/Smad signaling pathway.
Clinical Associations: Circulating MIF levels are independently associated with AF type, disease burden, atrial fibrosis extent, and long-term adverse outcomes.
Therapeutic Potential: Direct MIF inhibition or blockade of downstream signaling has shown antiarrhythmic potential in various animal models.
Key Findings:
MIF is a multifunctional cytokine involved in the initiation and perpetuation of AF.
MIF levels correlate with AF type, disease burden, and long-term outcomes such as heart failure and stroke.
MIF has both pro-inflammatory and antioxidant functions, complicating therapeutic targeting.
Interpretation:
Future research should focus on the molecular mechanisms of MIF in AF, including its role in atrial remodeling and potential therapeutic strategies.
Limitations:
Current understanding of MIF in AF is fragmented and lacks systematic synthesis, which may hinder therapeutic advancements.
The relative contribution of MIF may vary across different AF subtypes.
Conclusion:
Addressing the molecular mechanisms and therapeutic targeting of MIF is essential for advancing AF management.
